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The year under review has seen a remarkable proliferation of
papers on dengue. Four prospective studies have been carried
out across the dengue belt, many groups have been pushing at
the question of pathogenesis of dengue haemorrhagic fever,
and a breakthrough has been achieved in the development of a
mouse model for human dengue haemorrhagic fever. Curr Opin
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Introduction
The four dengue virus serotypes (DEN-1 to DEN-4)
have co-circulated in Southeast Asia for several decades,
with the ®rst recognised epidemic of dengue haemor-
rhagic fever (DHF) in Manila, the Philippines, in 1953/
1954. In the next two decades, epidemic DHF spread
throughout Southeast Asia to become a leading cause of
morbidity and mortality among children throughout the
region. In the latter years of the 1970s to the 1980s,
epidemiological and clinical research on DHF was
centred in Bangkok, Thailand, where the insightful
studies of local doctors (most notably Dr Suchitra
Nimannitya of Children's Hospital, Bangkok), in colla-
boration with other scientists established the basis for
the World Health Organization (WHO) classi®cation for
grading DHF, ®rst published in 1986 [1] and later
updated in 1997 [2].
DHF is thus distinguished from classical dengue fever
by the presence of the hallmarks of haemorrhagic fever,
characterized by vascular permeability and consequently
haemoconcentration. It is important to recognize that
DHF is not merely a febrile disease with haemorrhagic
manifestations, however severe, but is a qualitatively
distinct, potentially life-threatening leaky capillary syn-
drome. The WHO criteria for making a diagnosis of
DHF are clear: it is a febrile illness with thrombocyto-
penia of 100 0006106/l or less and a haematocrit raised
20% or more above the norm. In patients with DHF
grade I, a positive tourniquet test is the only haemor-
rhagic manifestation, whereas in DHF grade II, spon-
taneous bleeding occurs. Grades III and IV are also
referred to as dengue shock syndrome (DSS). When
patients experience circulatory failure with narrowing of
the pulse pressure, and a rapid and weak pulse, they are
said to have DHF grade III, whereas those in profound
shock with no detectable blood pressure and pulse have
DHF grade IV [1,2].
Neurological dengue
Besides the well characterised dengue fever and DHF, it
has long been recognised that patients with dengue
infection may present with `unusual manifestations',
including fulminant hepatitis, encephalopathy and en-
cephalitis [3±12]. Although most of these reports are case
descriptions rather than prospective clinical studies,
Solomon and coworkers [13..] have now corrected this
de®ciency in an excellent study of the neurological
manifestations of dengue in Vietnam. Interestingly, this
was not designed as a study of dengue infection
471
speci®cally, but rather a study of central nervous system
(CNS) infections in children and adults. Sixteen out of
378 (4.2%) patients with CNS infections during the
study period (1995) had evidence of dengue virus
infection compared with four out of 286 (1.4%) hospital
control subjects who had been admitted with diphtheria
(children) or typhoid (adults). In addition to the 16
patients identi®ed in the 1995 study period, Solomon
and coworkers [13 ..] also included another ®ve patients
identi®ed subsequently, and the paper goes on to
discuss these 21 patients. Twelve of these patients did
not have any characteristic features of dengue on
admission; 10 were encephalopathic and the authors
ask the question: `Should such patients be considered to
have dengue encephalitis?' However, seven of the nine
patients with a neurological diagnosis of `encephalitis' (as
opposed to encephalopathy or hepatic encephalopathy)
had no classical features of dengue infection.
In a dengue endemic area, during a dengue season, a
high rate of inapparent or subclinical dengue infection
occurs, and it is therefore necessary to rule out the
possibility that the dengue infection detected in such
cases is merely coincidental. The authors have at-
tempted to do this fairly convincingly for a range of
possible aetiologies. Most important of these is Japanese
encephalitis virus (JEV), which is highly endemic in
Vietnam and other parts of Southeast Asia, and is
probably the most important cause of encephalitis in
the region [14]. No JEV was grown from the serum or
cerebrospinal ¯uid (CSF) of these patients, but it is
extremely rare to grow JEV from peripheral specimens,
even from patients with con®rmed Japanese enceph-
alitis. Indeed, JEV isolates from human infection are
best obtained from brain tissue at autopsy [15]. How-
ever, it is possible to demonstrate the absence of JEV
genome in the CSF by reverse transcriptase±polymerase
chain reaction (RT±PCR), and it is a pity the study did
not include this very important evidence to make a more
convincing argument that the seven encephalitis cases
with no features of dengue fever or DHF probably did
indeed have dengue encephalitis.
The issue, however, is not whether dengue infection can
cause neurological disease, but whether dengue viruses
can replicate in the CNS in a natural infection. None of
the putative `dengue encephalitis' cases in the Vietnam
study had a CSF isolate, although two of these did have
evidence of dengue genome in the CSF by RT±PCR.
Rosen and coworkers [16..] provided an answer to this
very question. Tissues from 18 fatal DHF cases were
tested for the presence of dengue virus genome by
RT±PCR, and the ®ndings (14 out of 16 liver specimens
had dengue virus RNA) con®rmed earlier studies
suggesting dengue virus infection of the liver [17,18].
However, the absence of dengue virus RNA in all 44
samples of brain tissue from 15 patients is noteworthy.
The authors point out that encephalopathy is common in
severe dengue and that 12 of the patients in the study
did have convulsions or encephalitis, thus con®rming
that dengue virus replication in the CNS, if it does occur,
must be rare.
Dengue haemorrhagic fever criteria and
disease severity
In this context, it is important to realise that the WHO
criteria for the diagnosis of dengue fever and DHF were
meant to underscore the new clinical entity (DHF)
recognised in Southeast Asia at that time, and to provide
the guidelines for standardised grading, not of disease
severity as such, but of the spectrum of the manifes-
tation of haemorrhagic fever. That patients may present
with hepatic or neurological or other manifestations does
not negate these very well established and accepted
criteria. Therefore recent attempts to introduce different
case de®nitions [19 .,20] should be approached with
caution. Murgue and coworkers [19 .] were concerned
that the WHO classi®cation did not adequately account
for disease severity, and provided data to show that in a
retrospective study of laboratory con®rmed dengue
infections, six out of 10 fatal cases were classi®ed as
dengue fever, and fatality in these dengue fever cases
was attributed to multisystem failure, particularly severe
hepatic disorders. Rigau-Perez and Bonilla [20], on the
other hand, were concerned with obtaining more
sensitive de®nitions for DHF, but were well aware that
any modi®ed case de®nitions should be evaluated in
prospective studies before general adoption.
Nearly three decades after the ®rst Southeast Asian
DHF epidemic, South America experienced its ®rst
DHF epidemic in Cuba in 1981. This was followed in
1989 by Venezuela, and then Brazil in 1990. DHF is now
endemic in many countries in the Americas [21]. Most of
the DHF cases seen in this emerging problem in the
Americas have been associated with DEN-2. Rico-Hesse
and coworkers [22] showed that there has been an
introduction of Southeast Asian genotypes to the
Americas, and postulated that this may account for the
increase in DHF in these countries in the past decade.
The conclusions of their study have been strengthened
by more recent data showing that there are sequence
differences in the 5'NTR and the 3'NTR of Southeast
Asian and American genotypes of DEN-2 that give rise
to different secondary structures at these two ends of the
viral genome [23 .]. Although it is intriguing that isolates
from two DHF cases (Jamaica in 1983 and Venezuela in
1990) belonged to the Southeast Asian genotype,
whereas isolates from dengue fever cases (Venezuela
1987, Mexico 1992, Peru 1995, Peru 1996) all belonged
to the American genotype, many more strains need to be
analysed before any ®rm conclusions can be made.
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The spread of DHF to the Caribbean and to the
Americas has paved the way for several prospective
epidemiological studies in the spirit of the Rayong study
in Thailand in the early 1980s [24]. Watts and coworkers
[25 ..] studied dengue infection in Iquitos, Peru, from
1990. An epidemic of mild dengue (predominantly
DEN-2) was recognized between May and October
1995. As there had been serological evidence of DEN-1
infection previously, this outbreak provided an oppor-
tunity to investigate sequential DEN-1 to DEN-2
infection. Unlike the Rayong study, in which a ®fth of
the children with sequential DEN-1 to DEN-2 infection
had DSS, in Iquitos no DHF was observed. The authors
ascribed this ®nding to the fact that the DEN-2 viruses
isolated in the Peru outbreak of 1995 were of the
American genotype, and probably did not have the
potential to cause DHF.
Do we ®nally have a handle on pathogenesis then? Is it
going to be as simple as this ± that Southeast Asian
genotypes have DHF-causing potential and others do
not? Preliminary data from the ®rst year of another
prospective study [26 .], in Yogyakarta, Indonesia,
revealed that the DEN-1 to DEN-2 sequential infection
experienced by 31 children in this Southeast Asian town
did not yield any DHF. Clearly more work needs to be
done. The DEN-2 viruses from the study need to be
sequenced and genotyped, for it is conceivable that the
American genotype is also found in Southeast Asia.
Alternatively, the master key to understanding the
pathogenesis of DHF is not yet in our hands.
Viraemia and disease severity
In a fourth prospective study published during this
review period, Murgue and coworkers [27] investigated
the duration and magnitude of viraemia in children in a
DEN-2 outbreak in French Polynesia in 1996±1997.
Using the presence of viral RNA in the plasma as a
surrogate for viraemia, the investigators determined that:
(i) the mean duration of viraemia was lower in dengue
fever than in DHF patients; (ii) the mean viraemia titres
were higher in patients with DHF than those with
dengue fever; (iii) both the above mean values were not
signi®cantly different between primary and secondary
dengue. In seven patients, virus RNA was still
detectable in the last sample (one on day 4 and six on
day 5). These patients seem to have been excluded from
the analysis, and if so, the mean duration of viraemia
(overall mean 4.4+0.9 days), as determined by RT±
PCR, could actually be longer than estimated. Depend-
ing on how these seven cases were distributed between
the dengue fever and DHF categories, the determina-
tions of mean duration and the magnitude of viraemia
could tell rather different stories. The authors concluded
that their results did not support the infection enhance-
ment hypothesis. I fail to understand why.
Vaughn and coworkers [28..] investigated viraemia titres
in serial plasma samples from 168 children in Bangkok
who had dengue virus infection. This work involved
tremendous effort because the quantitation and duration
of viraemia was determined by inoculating dilutions of
plasma samples intrathoracically into mosquitoes. Unlike
PCR-based methods that determine the presence of viral
RNA, whether associated with viable virus or not, the
methods used in that study actually gave a picture of
how much viable virus was present. The results showed
that viraemia during primary infection was prolonged
compared with secondary infections. This is in contrast
to the data of Murgue and coworkers [27], but can easily
be explained if we consider the fact that in a secondary
immune response to dengue infection there will be
circulating antibody binding to and inactivating virus at
later stages in the course of the illness. These inactivated
viruses would be detected in a PCR-based assay but not
in a biological assay. The study also showed that the rate
of virus clearance was faster in patients experiencing
secondary compared with primary infection, and was also
faster in those with DHF than those with dengue fever.
Incidentally, data from the study also con®rm that at the
time of defervescence, when the platelet counts drop
and the characteristic vascular permeability occurs in
DHF, there is little or no viable virus in the circulation,
giving further credibility to the argument that these
events are mediated by processes not directly related to
infection, but rather to mediators such as cytokines
[29,30 .].
Another ®nding from the Bangkok study [28 ..] is that
the higher the peak viraemia titre, the greater the pleural
effusion. If pleural effusion is taken as a measure of the
severity of DHF, these data show that higher viraemia
does indeed occur in children with severe DHF. Both
peak viraemia titre and secondary immune responses
were shown to correlate with the severity of DHF. As
the authors pointed out, this is consistent with both of
the dominant hypotheses of dengue pathogenicity: a
virulent virus might be expected to replicate to higher
titres, just as antibody-dependent enhancement (ADE)
is expected to produce higher viraemias in patients with
secondary immune responses.
We are fortunate that the fascinating problem of how co-
circulating dengue virus serotypes may cause such a
wide spectrum of disease has caught the attention of
eminent epidemiologist Anderson. In two papers from
his group [31,32], the effect of ADE on transmission
dynamics was explored using mathematical models. The
take-home message is that ADE may explain those
cyclical dengue epidemics we are so familiar with in
Southeast Asia [31]. Furthermore, statistically rigorous
methods applied to data from Thailand supported a role
for ADE in the observed epidemiological patterns [32].
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Despite the advances made in recent years, the
pathogenesis of DHF remains poorly understood. It
would seem that even if some dengue viruses have
DHF-causing potential and others might not, in the
quest for a vaccine against dengue, we would do well to
account for the immune potentiation effects of sequential
dengue infection. It is thus imperative that suitable
animal models are developed for testing vaccine candi-
dates, and that this testing involves not merely the
measurement of protective responses in a relatively short
period of time, as described by Velzing and coworkers
[33 .] in their comparison of protective immunity in a
monkey model. In that study, involving three groups of
two cynomolgus monkeys, each pair was either immu-
nized with a candidate live attenuated vaccine, a
recombinant baculovirus subunit vaccine consisting of
the envelope protein of DEN-2, or was mock-immunised
with phosphate buffered saline. The humoral immune
response of each of the monkeys was carefully tracked by
enzyme-linked immunosorbent assay, haemagglutination
inhibition tests and virus neutralization tests before and
after challenge. The presence of virus after challenge was
determined using RT±PCR as well as virus isolation, and
the authors concluded that the live attenuated candidate
vaccine did indeed protect the monkeys against virus
challenge, whereas the envelope protein subunit vaccine
may not have been potent enough to protect. It was most
interesting that in one of the two monkeys receiving the
subunit vaccine, virus was isolated 9 days after challenge,
whereas both control monkeys no longer had virus
detected either by RT±PCR or by isolation by this time.
Immune potentiation?
Mouse model
An elegant mouse model for dengue virus infection has
now been described [34 ..], which may be useful in
studying various aspects of the pathogenesis of DHF. A
human hepatocarcinoma cell line, HepG2, known to
support dengue virus replication [35,36] was trans-
planted into severe combined immunode®cient (SCID)
mice. Such HepG2-grafted mice were infected with
DEN-2 virus, and the authors showed very convincingly
that the mice developed many of the features of DHF,
including thrombocytopenia and increased haematocrit.
Virus inoculated intraperitoneally was detected in the
serum and in the liver, and also induced paralysis, at
which point virus was also detected in the brain, thus
bringing us back to the dengue neurology study [13..]
with which this review began.
Conclusion
There is still much to learn about the pathogenesis of
DHF. With the global spread of dengue virus infection,
we also need to understand more about the correlates of
disease severity and to relate these to host as well as
virus-determined factors.
References and recommended reading
Papers of particular interest, published within the annual period of review, have
been highlighted as:
. of special interest
. . of outstanding interest
1 World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment
and control. Geneva: WHO; 1986.
2 World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment
and control, 2nd ed. Geneva: WHO; 1997.
3 Sumarmo , Wulur H, Jahja E, et al. Encephalopathy associated with dengue
infection. Lancet 1978; 1:449±450.
4 Kho LK, Sumarmo , Wulur H, et al. Dengue haemorrhagic fever accompanied
by encephalopathy in Jakarta. SEA J Trop Med Publ Health 1981; 12:583±
590.
5 Nimmannitya S, Thisyakorn U, Hemsrichart V. Dengue haemorrhagic fever
with unusual manifestations. SEA J Trop Med Publ Health 1987; 18:398±
406.
6 Jirapinyo P, Treetrakarn A, Vajaradul A, Suvatte V. Dengue haemorrhagic
fever: a case report with acute hepatic failure, protracted hypocalcemia,
hyperamylasemia and an enlargement of the pancreas. J Med Assoc Thai
1988; 71:528±532.
7 Hendarto SK, Hadinegoro SR. Dengue encephalopathy. Acta Paed Jap
1992; 34:350±357.
8 Lum LCS, Lam SK, George R, Devi S. Fulminant hepatitis in dengue
infection. SEA J Trop Med Publ Health 1993; 24:467±471.
9 Patey O, Ollivaud J, Breuil J, Lafaix C. Unusual neurologic manifestations
occurring during dengue fever infection. Am J Trop Med Hyg 1993; 48:793±
802.
10 Lum LCS, Lam SK, Choy S, et al. Dengue encephalitis: a true entity? Am J
Trop Med Int Health 1996; 54:256±259.
11 Hommel D, Talarmin A, Deubel V, et al. Dengue encephalitis in French
Guiana. Res Virol 1998; 149:235±238.
12 Mohan B, Patwari AK, Anand VK. Hepatic dysfunction in childhood dengue
infection. J Trop Pediatr 2000; 46:40±43.
. .
13 Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of
dengue infection. Lancet 2000; 355:1053±1059.
This is a unique prospective study of neurological dengue in southern Vietnam and
includes a description of the clinical features seen in a group of 21 patients. There
is even an attempt to include enough virology to suggest that the viruses isolated
from these patients are from the same lineage as the viruses from patients with
DHF in the same season.
14 Solomon T, Dung NM, Kneen R, et al. Japanese encephalitis. J Neurol,
Neurosurg Psychiatry 2000; 68:405±415.
15 Innis BL. Japanese encephalitis. In: Exotic viral infections. Porterfield JS
(editor). London: Chapman and Hall; 1995. pp. 147±174.
. .
16 Rosen L, Drouet M-T, Deubel V. Detection of dengue virus RNA by reverse
transcription±polymerase chain reaction in the liver and lymphoid organs but not
in the brain in fatal human infection. Am J Trop Med Hyg 1999; 61:720±724.
The use of RT±PCR to determine the presence of dengue virus RNA in autopsy
tissue is presented with careful attention to detail to convince the reader that the
methods used have been optimised to give a high sensitivity. Negative results are
therefore all the more convincing.
17 Rosen L, Khin M-M, Tin-U . Recovery of virus from the liver of children with
fatal dengue: reflections on the pathogenesis of the disease and its possible
analogy with that of yellow fever. Res Virol 1989; 140:351±360.
18 Kangwanpong D, Bhamarapravati N, Lucia HL. Diagnosing dengue virus
infection in archived autopsy tissues by means of the in-situ PCR method: a
case report. Clin Diagn Virol 1995; 3:165±172.
.
19 Murgue B, Deparis X, Chungue E, et al. Dengue: an evaluation of dengue
severity in French Polynesia based on an analysis of 403 laboratory-confirmed
cases. Trop Med Int Health 1999; 4:765±773.
Although designed to test the validity of the WHO classification, this retrospective
study provides much interesting data on clinical and laboratory correlates of
disease severity.
20 Rigau-Perez JG, Bonilla GL. An evaluation of modified case definitions for the
detection of dengue haemorrhagic fever. Puerto Rico Association of
Epidemiologists. P R Health Sci J 1999; 18:347±352.
21 Gubler DJ, Clark GG. Dengue/dengue haemorrhagic fever: the emergence
of a global health problem. Emerg Infect Dis 1995; 1:55±57.
Tropical and travel-associated diseases474
22 Rico-Hesse R, Harrison LM, Salas RA, et al. Origins of dengue type 2 viruses
associated with increased pathogenicity in the Americas. Virology 1997;
230:244±251.
.
23 Leitmeyer KC, Vaughn DW, Watts DM, et al. Dengue virus structural
differences that correlate with pathogenesis. J Virol 1999; 73:4738±4747.
A massive effort in sequencing the complete genomes of a number of Southeast
Asian and American strains of DEN-2. Even more remarkable is the fact that
sequencing was performed on viraemic primary specimens rather than on
passaged virus.
24 Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue
shock syndrome: a prospective epidemiological study in Rayong, Thailand.
Am J Epidemiol 1984; 20:653±669.
. .
25 Watts DM, Porter KR, Putvatana P, et al. Failure of secondary infection with
American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet
1999; 354:1431±1434.
A prospective epidemiological study covering the period from 1990 through the
epidemic of 1995 in Peru. The sequence of infection DEN-1 to DEN-2 was
reminiscent of the Thai study a decade earlier. However, in Peru, this sequence of
infection did not give rise to DHF.
.
26 Graham RR, Juffrie M, Tan R, et al. A prospective seroepidemiologic study on
dengue in children four to nine years of age in Yogyakarta, Indonesia I. Studies in
1995±1996. Am J Trop Med Hyg 1999; 61:412±419.
Preliminary data from this Indonesian study show that sequential DEN-1 to DEN-2
infections did not give rise to DHF/DSS, but that the sequence DEN-2 to DEN-1
did result in DHF/DSS in 7.3% of these children.
27 Murgue B, Roche C, Chungue E, Deparis X. Prospective study of the
duration and magnitude of viraemia in children hospitalised during the 1996±
1997 dengue-2 outbreak in French Polynesia. J Med Virol 2000; 60:432±
438.
. .
28 Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody
response pattern, and virus serotype correlate with disease severity. J Infect Dis
2000; 181:2±9.
The effort put into this study has been tremendous. It addresses many important
questions regarding virus load and humoral responses in the pathogenesis of
DHF. The study sample is large and is not limited to a single dengue virus
serotype.
29 Rothman AL, Ennis FA. Immunopathogenesis of dengue haemorrhagic fever.
Virology 1999; 257:1±6.
.
30 Green S, Vaughn DW, Kalayanarooj S, et al. Early immune activation in acute
dengue illness is related to development of plasma leakage and disease
severity. J Infect Dis 1999; 179:755±762.
A nicely designed study with clear graphic representations of the associations of
various mediators with markers of disease severity.
31 Ferguson N, Anderson R, Gupta S. The effect of antibody-dependent
enhancement on the transmission dynamics and persistence of multiple-strain
pathogens. Proc Natl Acad Sci USA 1999; 96:790±794.
32 Ferguson NM, Donnelly CA, Anderson RM. Transmission dynamics and
epidemiology of dengue: insights from age-stratified sero-prevalence surveys.
Phil Trans R Soc Lond B Biol Sci 1999; 354:757±768.
.
33 Velzing J, Groen J, Drouet MT, et al. Induction of protective immunity against
dengue virus type 2: comparison of candidate live attenuated and recombinant
vaccines. Vaccine 1999; 17:1312±1320.
An important study of humoral immune responses in cynomolgus monkeys. Using
monkeys is always an expensive exercise, and this and other (ethical)
considerations dictate that the numbers of animals used remain too small to be
useful for meaningful generalisations.
. .
34 An J, Kimura-Kuroda J, Hirabayashi Y, Yasui K. Development of a novel mouse
model for dengue virus infection. Virology 1999; 263:70±77.
This paper is the highlight of the year under review. A brilliant attempt to create an
animal model that mimics human disease. This mouse model will surely be the
means by which the long awaited breakthroughs into the mysteries of DHF
pathogenesis will become possible.
35 Marianneau P, Megret F, Olivier R, et al. Dengue 1 virus binding to human
hepatoma HepG2 and simian Vero cell surface differs. J Gen Virol 1996;
77:2547±2554.
36 Marianneau P, Cardono A, Edelman L, et al. Dengue virus replication in
human hepatoma cells activates NF-kB which in turn reduces apoptotic cell
death. J Virol 1997; 71:3244±3249.
Dengue haemorrhagic fever Cardosa 475
